Search results for: 'Actionable Strategy Enabling the Prague Smart City Future'

For a long time, drug discovery followed the same path and used conventional analysis methods for proposed targets. Today, changes in technology and the ability to study omics are transforming drug development. Personalized therapy is on the rise and promises to be more effective and efficient in addressing challenges. With growing interest in ...

04 Sep 2018  |  North America  |  Market Research

Digital Transformation in the Pharmaceuticals Industry—Companies-to-Action, 2018

Value-based Care, Patient Data Digitization, and Collaborative Technology Deployment Offer Investment Opportunities

Infographics

×

Key Issues Addressed

The pharmaceutical industry today is in a state of flux as it tries to maintain a delicate balance between the need for novel blockbuster drugs and the need for improved operational efficiencies in an increasingly competitive market space. As healthcare is becoming increasingly democratized, patients are emerging as key decision makers—digitally en...

31 Oct 2017  |  Global  |  Market Research

Global Digital Pathology Market, 2017 Companies-To-Action

Collaborative Business Models Embracing Artificial Intelligence Application in Novel Disease Areas to Drive Market Growth

Infographics

×

It is estimated that more than 19,000 pathologists would be needed to serve the US healthcare needs. However, the actual number is expected to be approximately 40% lesser. Similar trends are foreseen globally driven by aging population and widening application in areas such as cancer diagnostics, drug development, clinical trials, biomarker discove...

The global pharmaceutical industry is continuously evolving. with the rising need for novel therapies in the ever-changing disease landscape. As a result of rising prevalence of chronic infectious diseases as well as continuously growing number of cancer cases, market needs are shifting from traditional, small molecules to novel, large-molecule the...

Since the advent of stem cells reprogramming after the discovery of the differentiation factors that allow the creation of human induced pluripotent stem cells, researchers all around the world are strongly committed to develop novel methods to design and build human stem cells. Indeed, there is an increasing demand for the more efficient product...

Despite the term patient centricity gaining currency in the industry, there is a degree of variability in a companies’ approach and strategic priorities. Frost & Sullivan sees digitization playing a critical role in transforming the clinical trial model from traditional, high-cost, and difficult-to-access centralized settings to more patient-centri...

Scope of the report The research report includes the following segments: Product scope: Pharmaceutical Products Geographic scope: Ethiopia End-user scope: Pharmaceutical manufacturers, Pharmaceutical distributors, Healthcare providers, Contract Manufacturing Organisations (CMO) Revenue analysis and forecasts, drivers and restraints, business opp...

Pharmaceutical drug discovery and development suffers from declining success rates with new molecules, and the rate of return has shrunk from 16% in 2011 to almost 11% in 2018. Frost & Sullivan finds that traditional solutions focused primarily on data from limited sources and rule-based computational techniques used to address the understanding of...

After many years of basic research, regenerative medicine represents a remarkable foremost innovation in medical care. Comprising principles of stem cell technology and tissue engineering, also combining advanced biomaterials with small molecules and biologics, to replace or regenerate human tissues and organs and restore their functions, regenerat...